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creativecommons.org/licenses/by-nc-nd/Abstract Background: We assessed long-term cardiac safety and efficacy in patients with hu-
man epidermal growth factor receptor 2epositive early breast cancer treated with a trastuzu-
mab biosimilar (SB3) or its reference product, trastuzumab (TRZ), in a phase 3 study.
Methods: Patients who completed the phase 3 study could be enrolled in this extension study.
The outcomes included the incidence of symptomatic congestive heart failure (CHF), asymp-
tomatic significant left ventricular ejection fraction (LVEF) decrease, incidence of other car-
diac events, event-free survival (EFS), and overall survival. In post hoc analysis, the Cox
proportional hazards regression model was used to assess factors associated with EFS.
Results: A total of 367 patients were enrolled in the study (SB3, nZ 186; TRZ, nZ 181). The
median follow-up duration from the main study enrolment was 40.8 and 40.5 months for SB3
and TRZ, respectively. During the two-year follow-up after adjuvant therapy, incidence of
asymptomatic significant LVEF decrease was rare (SB3, nZ 1; TRZ, nZ 2), with all patients
recovering with LVEF  50%, and no cases of symptomatic CHF or other cardiac events wereCenter, 3 Rue de La Porte de L’Hoˆpital, INSERM 1109, Strasbourg, 67065, France.
nicancer.fr (X. Pivot).
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X. Pivot et al. / European Journal of Cancer 120 (2019) 1e92reported. At 3 years, the EFS was 91.9% with SB3 and 85.2% with TRZ. The number of pa-
tients with events was 17 (9.1%) with SB3 and 31 (17.1%) with TRZ [hazard ratio: 0.47, 95%
confidence interval: 0.26e0.87]. Antibody-dependent cell-mediated cytotoxicity (ADCC) ac-
tivity and the breast pathologic complete response rate were the factors associated with EFS.
Conclusion: Cardiotoxicity was rare in this extension study. EFS was higher with SB3 versus
TRZ, with post hoc analysis suggesting that a downward drift in ADCC activity was a
contributing factor.
Clinical trial registration numbers: NCT02771795 (EudraCT 2015-005663-17).
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
SB3 (Ontruzant [Samfenet in Korea]; Samsung
Bioepis Co., Ltd., Incheon, the Republic of Korea), an
approved biosimilar of the trastuzumab reference
product (hereafter referred to as TRZ), is registered in
Europe, the United States, the Republic of Korea and
Australia [1e3]. A phase 3 randomised controlled study
(NCT02149524, EudraCT 2013-004172-35; hereafter
referred to as the main study) was conducted on 875
women with human epidermal growth factor receptor 2
(HER2)epositive early or locally advanced breast can-
cer treated in the neoadjuvant setting [4]. The breast
pathologic complete response (bpCR) rates in the per-
protocol set were 51.7% and 42.0% with SB3 and
TRZ, respectively. The adjusted ratio of bpCR was
1.259 (90% confidence interval [CI], 1.112e1.426), which
was within the predefined equivalence margins of 0.785
and 1.546. However, the adjusted difference in the per-
protocol set was 10.70% (95% CI, 4.13e17.26), with
the upper limit of the 95% CI outside the equivalence
margin of 13.0%. A similar trend was observed in total
pathologic complete response (tpCR) rates. No differ-
ence was observed between SB3 and TRZ in event-free
survival (EFS) and overall survival (OS) at 1-year
follow-up [5].
On monitoring physicochemical and biological
properties of TRZ for the development of SB3, a
downward drift in the level of glycosylation, FcgRIIIa
binding activity, and antibody-dependent cell-mediated
cytotoxicity (ADCC) activity was observed in TRZ lots
with expiry dates from August 2018 to December 2019,
as previously reported by Kim et al. [6]. Some of the
drifted TRZ lots were used in the phase 3 study and may
have contributed to the observed difference between
arms in terms of bpCR and tpCR rates in the main
study [4].
The objective of this long-term extension of the main
study was to investigate cardiac safety, EFS and OS in
patients who received SB3 or TRZ. A post hoc analysis
aimed to assess the factors contributing to the observed
difference in EFS.2. Methods
The extension study (NCT02771795, EudraCT 2015-
005663-17) was conducted in accordance with the ethical
principles of the Declaration of Helsinki and consistent
with Good Clinical Practice guidelines. The extension
study and protocol were approved by independent ethics
committees or institutional review boards.
2.1. Study design and participants
The extension study was an observational cohort study
from the main study; inclusion and exclusion criteria for
the main study were previously reported [4]. After reg-
ulatory recommendation, patients from prespecified
countries (Bosnia and Herzegovina, Bulgaria, the Czech
Republic, France, Poland, Romania, the Russian
Federation and Ukraine) who completed the neo-
adjuvant treatment, surgery and adjuvant treatment and
provided written informed consent were eligible to
participate in the treatment-free extension study. The
participants in the extension study had not experienced
symptomatic cardiac events during the main study and
had not experienced early recurrence while they received
adjuvant therapy.
2.2. Assessments
The patients will be followed up for 5 years after the end
of the main study. Follow-up visits were recommended
every 6 months for 2 years and then yearly for an
additional 3 years. During follow-up visits, physical
examination including clinical breast examination,
mammography, left ventricular ejection fraction
(LVEF) measurement (2D echocardiography or the
Multigated acquisition (MUGA) scan) and monitoring
of cardiac events was performed in the routine care
setting. The primary outcome of this extension study
was the incidence of symptomatic congestive heart fail-
ure (New York Heart Association class IIeIV
confirmed by a cardiologist and accompanied by a sig-
nificant LVEF decrease) and the incidence of an
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decrease of 10% from the baseline with a resulting
value of <50%. The incidences of cardiac death and
other significant cardiac conditions (e.g., acute
myocardial infarction, severe arrhythmia, ischaemic
heart disease and valvular dysfunction) were secondary
safety outcomes. Secondary efficacy outcomes were EFS
(time from the date of randomisation to the date of
disease recurrence, progression [local, regional,
distant or contralateral] or death) and OS (time from the
date of randomisation to the date of death, regardless of
cause).
2.3. Statistical analysis
Demographics and baseline disease characteristics are
summarised using descriptive statistics for patients who
were enrolled in this extension study from the main
study. Including efficacy data from the main and
extension studies, Kaplan-Meier curves for EFS and OS
were generated by treatment arms (SB3 and TRZ),
which were assigned in the main study. Hazard ratios
(HRs) with 95% CI were determined for SB3 over TRZ
based on a stratified Cox proportional hazards regres-
sion model adjusted for stratification factors (hormone
receptor status, breast cancer type and region).
Among the 25 TRZ lots that were used in the main
study, 12 TRZ lots were obtained, and their ADCC
activities were analysed (Supplementary Figure 1A). The
ADCC activity for the remaining 13 TRZ lots was
assumed based on their expiry dates: TRZ lots with
expiry dates from August 2018 to December 2019 were
assumed to have a drift in ADCC activity based on the
analysis results from the study by Kim et al. [6].
Of the 25 TRZ lots, 13 were classified as having a
drift in ADCC activity (eight based on the available
analysis results and five based on expiry dates). The
ADCC activity of the remaining 12 lots was considered
to be in the normal range (four based on the available
analysis results and eight based on expiry dates). Dis-
tribution of TRZ vials used in the phase 3 study by site
and visit date can be found in Supplementary Figure 1B.
Among patients who were treated with TRZ, those
exposed to at least one vial from a drifted TRZ lot
during the neoadjuvant period were designated as the
‘Drifted TRZ’ group, and those who were never exposed
to any vials from a drifted TRZ lot during the neo-
adjuvant period were designated as the ‘non-drifted
TRZ’ group. Results based on exposure during the
neoadjuvant period are mainly presented in this study;
however, the same analysis was performed by exposure
to at least one vial of the drifted TRZ lot during the
adjuvant period or the entire treatment period.
As for post hoc analysis, the Cox proportional haz-
ards regression model was used to find the factors that
are associated with EFS. The backward variable selec-
tion method was used to select statistically significantfactors. The HR with its respective p value for each
covariate was presented. The significance level for
eliminating a factor from the model in the backward
selection method was 0.10. Treatment arm (SB3/TRZ),
bpCR (no/yes), tpCR (no/yes), ADCC activity (drifted/
non-drifted), hormone receptor status (oestrogen
receptore and progesterone receptorenegative/posi-
tive), breast cancer type (locally advanced/operable), age
(<45 years/> Z 45 years) and menopausal status (no/
yes) were considered as factors. Because bpCR and
tpCR were highly correlated to each other, they were
analysed in separate models.
Kaplan-Meier curves for EFS and OS were generated
by the treatment group and ADCC activity (SB3, non-
drifted TRZ and drifted TRZ). The stratified Cox pro-
portional hazards regression model with ADCC activity
(or treatment arm) and bpCR as covariates were used to
estimate HRs and the corresponding 95% CI of the
treatment arm (SB3/non-drifted TRZ) and ADCC ac-
tivity (non-drifted TRZ/drifted TRZ), respectively.
3. Results
3.1. Patients
The extension study was initiated in April 2016 and is
ongoing. Patient disposition is shown in Fig. 1. Of 875
patients randomised in the main study (SB3, n Z 437;
TRZ, n Z 438), a total of 367 patients (SB3, n Z 186;
TRZ, nZ 181) were enrolled in the extension study. As
of the cut-off date (12th September 2018), the study was
ongoing for 339 patients (SB3, nZ 175; TRZ, nZ 164).
The median (range) follow-up duration from enrolment
for the main study was 40.8 (18.4e52.3) and 40.5
(23.4e51.8) months for SB3 and TRZ, respectively. The
most common reason for early termination was death in
both arms (SB3, n Z 5; TRZ, n Z 13). Demographics
and baseline disease characteristics were well balanced,
with no apparent differences between the SB3 and TRZ
arms (Table 1).
3.2. Cardiac safety
Symptomatic congestive heart failure was not reported
in either the SB3 or TRZ arm. There were three
asymptomatic significant LVEF decreases reported
during the extension study (SB3, n Z 1; TRZ, n Z 2).
No other cardiac-related events, including cardiac
death, occurred. Changes in LVEF over time were
similar between the SB3 and TRZ arms (Fig. 2).
3.3. Efficacy
EFS in the SB3 and TRZ arms is shown in Fig. 3A. The
number of patients with events was 17 (9.1%) in the SB3
arm and 31 (17.1%) in the TRZ arm, with a HR (SB3/
Fig. 1. Patient disposition. TRZ, trastuzumab reference product.
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was 91.9% in the SB3 arm and 85.2% in the TRZ arm.
OS in the SB3 and TRZ arms is shown in Fig. 3B.
The number of deaths was 5 (2.7%) in the SB3 arm and
13 (7.2%) in the TRZ arm, with a HR (SB3/TRZ) of 0.37
(95% CI, 0.13e1.04). The 3-year OS rate was 97.0% in
the SB3 arm and 92.9% in the TRZ arm.
3.4. Post hoc analysis results
The results of the Cox proportional hazards regression
models with backward elimination showed that, among
the covariates analysed, ADCC activity and bpCR (or
tpCR) were the factors that were associated with EFS at
the 0.1 significance level (Fig. 4).
3.4.1. Efficacy by exposure to drifted TRZ during the
neoadjuvant period
The number of patients in the non-drifted and drifted
TRZ groups was 55 and 126, respectively. De-
mographics and baseline disease characteristics were
well balanced between both groups (Table 1).
EFS is shown by exposure to drifted TRZ during the
neoadjuvant period in Fig. 3C. The percentage ofpatients with events was significantly higher in the
drifted TRZ group (n Z 26, 20.6%) than in the non-
drifted TRZ group (n Z 5, 9.1%), with a HR (drifted
TRZ/non-drifted TRZ) of 5.31 (95% CI, 1.74e16.25).
The 3-year EFS rate was 81.7% in the drifted TRZ
group and 92.7% in the non-drifted TRZ group. No
significant difference in EFS was observed between the
SB3 and non-drifted TRZ group (HR, 0.93 [95% CI,
0.31e2.85]; Fig. 3C).
OS is shown by exposure to drifted TRZ during the
neoadjuvant period in Fig. 3D. A higher percentage of
deaths was observed in the drifted TRZ group (n Z 12,
9.5%) than in the non-drifted TRZ group (nZ 1, 1.8%),
with a HR (drifted TRZ/non-drifted TRZ) of 7.96 (95%
CI, 0.95e67.00). The 3-year OS rate was 89.4% in the
drifted TRZ group and 100% in the non-drifted TRZ
group. OS was comparable between the SB3 and non-
drifted TRZ groups (HR, 0.53 [95% CI, 0.05, 5.51];
Fig. 3D).
3.4.2. Efficacy by exposure to drifted TRZ during the
adjuvant or the entire treatment period
The results analysed by exposure to drifted TRZ during
the adjuvant treatment period (Supplementary Table
Table 1
Patient demographics and baseline disease characteristics.
Characteristic SB3 (N Z 186) TRZ (N Z 181)
All Non-drifteda (n Z 55) Driftedb (n Z 126)
Age, median (minimum, maximum), y 52 (27, 65) 53 (22, 65) 52 (22, 63) 53 (22, 65)
Race, n (%)
White 176 (94.6) 171 (94.5) 50 (90.9) 121 (96.0)
Asian 3 (1.6) 2 (1.1) 0 (0) 2 (1.6)
Other 7 (3.8) 8 (4.4) 5 (9.1) 3 (2.4)
Menopause, n (%) 92 (49.5) 98 (54.1) 31 (56.4) 67 (53.2)
ECOG performance status, n (%)
0 162 (87.1) 150 (82.9) 45 (81.8) 105 (83.3)
1 24 (12.9) 31 (17.1) 10 (18.2) 21 (16.7)
LVEF, mean (SD), % 65.5 (4.8) 64.8 (5.3) 65.1 (5.7) 64.7 (5.2)
Breast cancer type, n (%)
Operable 124 (66.7) 120 (66.3) 37 (67.3) 83 (65.9)
Locally advanced 56 (30.1) 55 (30.4) 15 (27.3) 40 (31.7)
Inflammatory 6 (3.2) 6 (3.3) 3 (5.5) 3 (2.4)
Histopathologic tumour type, n (%)
Invasive ductal carcinoma 179 (96.2) 176 (97.2) 53 (96.4) 123 (97.6)
Invasive lobular carcinoma 4 (2.2) 1 (0.6) 0 (0) 1 (0.8)
Other 3 (1.6) 4 (2.2) 2 (3.6) 2 (1.6)
Hormone receptor status, n (%)
ERþ/PRþ 90 (48.4) 67 (37.0) 17 (30.9) 50 (39.7)
ERþ/PR 31 (16.7) 32 (17.7) 11 (20.0) 21 (16.7)
ER/PRþ 4 (2.2) 6 (3.3) 1 (1.8) 5 (4.0)
ER/PR 61 (32.8) 76 (42.0) 26 (47.3) 50 (39.7)
Clinical T stage, n (%)
cT1 1 (0.5) 2 (1.1) 1 (1.8) 1 (0.8)
cT2 124 (66.7) 109 (60.2) 31 (56.4) 78 (61.9)
cT3 22 (11.8) 32 (17.7) 11 (20.0) 21 (16.7)
cT4 39 (21.0) 38 (21.0) 12 (21.8) 26 (20.6)
Clinical N stage, n (%)
cN0 45 (24.2) 40 (22.1) 9 (16.4) 31 (24.6)
cN1 104 (55.9) 104 (57.5) 36 (65.5) 68 (54.0)
cN2 30 (16.1) 24 (13.3) 8 (14.5) 16 (12.7)
cN3 7 (3.8) 13 (7.2) 2 (3.6) 11 (8.7)
Clinical TNM staging, n (%)
Stage IIA 38 (20.4) 33 (18.2) 9 (16.4) 24 (19.0)
Stage IIB 76 (40.9) 70 (38.7) 23 (41.8) 47 (37.3)
Stage IIIA 28 (15.1) 34 (18.8) 10 (18.2) 24 (19.0)
Stage IIIB 37 (19.9) 31 (17.1) 11 (20.0) 20 (15.9)
Stage IIIC 7 (3.8) 13 (7.2) 2 (3.6) 11 (8.7)
bpCR in the main study, n/N (%) 208/402 (51.7) 167/398 (42.0)
tpCR in the main study, n/N (%) 175/382 (45.8) 136/380 (35.8)
bpCR, breast pathologic complete response; ECOG, Eastern Cooperative Oncology Group; ER, oestrogen receptor; LVEF, left ventricular
ejection fraction; N, the number of subjects in the per-protocol set in the main study; PR, progesterone receptor; tpCR, total pathologic complete
response; TRZ, trastuzumab reference product; SD, standard deviation.
a Patients never exposed to any vials from a drifted TRZ lot during the neoadjuvant period.
b Patients exposed to at least one vial from a drifted TRZ lot during the neoadjuvant.
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during the entire treatment period (Supplementary
Table 2B) showed similar trends with those of the neo-
adjuvant setting.
4. Discussion
Cardiovascular safety profiles were comparable between
SB3 and TRZ during this extension study, with no
symptomatic congestive heart failure, cardiac deaths or
other significant cardiac conditions. The findings in thisextension study are consistent with those of other
studies that suggest low risk of developing cardiotoxicity
after completion of neoadjuvant and adjuvant trastu-
zumab [7e9], despite its use in combination with
anthracyclines [10e13].
In this 3-year follow-up, the SB3 arm was associated
with a significantly lower number of events counting for
EFS than that of the TRZ arm (HR, 0.47 [95% CI,
0.26e0.87]). The post hoc analysis suggests that the
observed difference in EFS between SB3 and TRZ may
have been contributed by the subgroup of patients
Fig. 2. Mean left ventricular ejection fraction over time. Error bars
represent standard deviations. TRZ, trastuzumab reference
product.
Fig. 3. KaplaneMeier curves for (A) EFS for SB3 and TRZ; (B) OS for
and (D) OS for SB3, non-drifted TRZ and drifted TRZ. Non-drifted TR
TRZ lot during the neoadjuvant period. Drifted TRZZ patients who
neoadjuvant period. CI, confidence interval; EFS, event-free survival; H
product.
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proportional hazards regression model, ADCC activity
and bpCR (or tpCR) were the factors associated with
EFS. The percentage of patients with events was 20.6%
and 9.1% in the drifted TRZ versus non-drifted TRZ
groups, respectively (HR, 5.31 [95% CI, 1.74e16.25]);
no significant difference was observed between SB3 and
the non-drifted TRZ group (HR, 0.93 [95% CI,
0.31e2.85]). Similar trends were observed for OS;
however, extended follow-up is needed to confirm the
finding.
pCR has been used as a surrogate end-point of sur-
vival in numerous clinical trials of neoadjuvant therapy
for breast cancer [12,14e17] and is considered a surro-
gate marker of survival in this population [18]. Our re-
sults are consistent with historical results showing that
pCR achievement is associated with improved long-term
survival in HER2-positive breast cancer (Fig. 4). Based
on the results from the Cox proportional hazardsSB3 and TRZ; (C) EFS for SB3, non-drifted TRZ and drifted TRZ;
ZZ patients who were never exposed to any vials from a drifted
were exposed to at least one vial from a drifted TRZ lot during the
R, hazard ratio; OS, overall survival; TRZ, trastuzumab reference
Fig. 4. Influential factors on EFS (A) with bpCR as a covariate and (B) with tpCR as a covariate. DriftedZ patients who were exposed to at
least one vial from a drifted TRZ lot during the neoadjuvant period. Non-driftedZ patients who were never exposed to any vials from a
drifted TRZ lot during the neoadjuvant period. Positive Z ER and/or PR positive. Negative Z ER and PR negative. Patients whose
bpCR or tpCR is missing are excluded from the model. ADCC, antibody-dependent cell-mediated cytotoxicity; bpCR, breast pathologic
complete response; CI, confidence interval; EFS, event-free survival; ER, oestrogen receptor; HR, hazard ratio; PR, progesterone re-
ceptor; tpCR, total pathologic complete response; TRZ, trastuzumab reference product.
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with EFS in both models (Fig. 4). This finding suggests
ADCC might be another factor influencing survival.
Drifted TRZ has previously been shown to be less able
to induce an ADCC response [6], and thus one of the
main reasons for the between-arm difference in EFS
rates could be a drifted ADCC response induced by
drifted TRZ.
ADCC is thought to be an important contributor to
the efficacy of trastuzumab [19e21], and amplification
of ADCC activity could be a promising area of research
[22]. Trastuzumab has been shown to induce ADCC in
peripheral blood mononuclear cells in HER2-amplified
and non-amplified breast cancer cell lines as well as in
trastuzumab-resistant breast cancer cell lines [19,20].
The ADCC response is triggered when the Fab and Fc
fragments of trastuzumab engage the tumour cell anti-
gen and Fc gamma receptor (FcgR) of the effector cell,
respectively [23]. In preclinical models, trastuzumab did
not arrest tumour cell growth in mice deficient in acti-
vating FcgR or in the presence of antibodies that dis-
rupted Fc binding [24]. Afucosylated trastuzumab was
demonstrated to have increased Fc binding, enhanced
ADCC and more than double the median progression-
free survival in mice, when compared with conven-
tional trastuzumab [25]. To our knowledge, our findingsare the first clinical results to support the hypothesis of a
relationship between ADCC activity and long-term
survival.
This report is limited in that it does not have suffi-
cient power to test the hypothesis of a relationship be-
tween ADCC activity and EFS, and the results are based
on a subset of patients from the main study population.
And the survival results by exposure to ADCC drift
were derived from a post hoc analysis and a dispro-
portionate number of patients in each group within the
TRZ arm, with ADCC activity data of only 12 TRZ lots
available.
In conclusion, in this extension study, the incidence of
cardiotoxicity was rare in both the SB3 and TRZ arms.
The EFS rate was higher in the SB3 versus TRZ arm, and
the differences could be attributed to a drift in ADCC
activity in some of the TRZ lots that were used during the
study. Our data support the hypothesis of a relationship
between ADCC activity and clinical outcomes in terms of
the response rate and long-term survival.Funding
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